BACKGROUND Low flow, low gradient, aortic stenosis is becoming increasingly recognized as a subgroup of severe aortic stenosis. Acceleration time (AT) has been correlated with severity of severe aortic stenosis (AS). We examined the epidemiology of Low flow, low gradient (LF/LG) severe AS and the correlation with AT to predict the valve area.
METHODS
We studied 138 consecutive patients diagnosed with severe AS and normal ejection fraction (>55%) by echocardiography. The mean age was 81AE10 yrs; 66% were females, 63% were African Americans and 86% had hypertension. Chi square test was used for comparing binary variables; student t-test for comparing means, and linear regression was performed using IBM SPSS.
RESULTS 47 (34%) patients had stroke volume index < 35 and 28 (20%) had low flow and low aortic mean gradient (<40 mmHg). There were no significant differences in gender and race distribution or past medical history in the groups divided based on LF/LG. The aortic valve area by continuity equation was 0.74AE0.16 vs 0.73AE0.14, nor was there a difference in AVA index, dimensionless index or EF. Mean gradient (45AE16 vs 27.5AE7 mmHg), as did peak gradient (73AE23 vs 48AE12 mmHg), stroke volume index (42.4AE10 vs 28AE5 ml/m2), ZVA (4.3AE1.4 vs 5.4AE1.8), average AT (113AE20 vs 94AE16 ms) and average ejection time (316AE31 vs 292AE37 sec) were significantly different (p value <.01). AT significantly and negatively correlated with AVA index in both the LF/LG (r -0.368, p <.01), and rest of the cohort group (r -0.414, p <.01). Adjusted for age, gender, race, and ejection fraction using linear multivariate regression analysis, AT and LF/LG were significant predictors of AVA index. CONCLUSIONS Acceleration time is significantly correlated with AVA index derived from the continuity equation in both traditional severe AS and in LF/LG severe AS, and is an independent predictor of AVA index. The utility of AT in differentiating the severe from moderate AS in LF/LG group needs to be evaluated. Figure 1A ) have not been previously reported. The primary objective of the TAVR-LM registry is to evaluate the clinical outcomes in patients undergoing TAVR plus LM PCI.
METHODS We retrospectively collected clinical, echocardiographic, computed-tomographic and angiographic characteristics in 204 patients undergoing TAVR plus LM PCI. One-hundred twenty-eight matched patient pairs were generated by performing 1:1 case-control matching between 167 patients with pre-existing LM stent undergoing TAVR and 1188 control patients undergoing TAVR without LM revascularization.
RESULTS One-year mortality (9.4% vs. 10.2%, p ¼ 0.83) was similar between the TAVR plus LM PCI cohort and matched controls ( Figure 1B) . One-year mortality after TAVR plus LM PCI was not different among patients with unprotected, compared to protected LM (7.8% vs. 8.1%, p ¼ 0.88); among those with ostial versus nonostial LM stents (10.3% vs. 15.6%, p ¼ 0.20); and among those undergoing LM PCI within 3 months, compared to those with LM PCI greater than 3 months prior to TAVR (7.4% vs. 8.6%, p ¼ 0.61). Unplanned LM PCI performed due to TAVR-related coronary complication, compared to planned LM PCI performed for pre-existing LM disease, resulted in increased 30-day (15.8% vs. 3.4%, p ¼ 0.013) and 1-year mortality (21.1% vs. 8.0%, p ¼ 0.071). 
